Low levels of vitamin B12 may worsen walking, cognition in Parkinson's patients

March 9, 2018 by Suzanne Leigh, University of California, San Francisco
Immunohistochemistry for alpha-synuclein showing positive staining (brown) of an intraneural Lewy-body in the Substantia nigra in Parkinson's disease. Credit: Wikipedia

A study of patients with early Parkinson's disease found that groups with lower levels of vitamin B12 faced on average a more rapid acceleration of both motor and cognitive symptoms, which slowed in some cases after taking a daily multivitamin.

In the two-year study, of vitamin B12 were tested in 680 patients who had recently been diagnosed with Parkinson's. Researchers led by first author Chadwick Christine, MD, a UCSF neurologist, also assessed patients' gait and mobility, ability to perform activities of daily living, cognition and symptoms of depression.

"Our findings demonstrate that low B12 levels are associated with greater walking and balance problems, possibly due to the known effect of B12 deficiency on the central and peripheral nervous systems," said Christine. "Alternatively, low B12 may have a direct effect on the progression of Parkinson's disease, or it may be a marker of an unknown associated factor, perhaps correlating with another aspect of the disease or nutritional status."

The study was published March 6, 2018, in the "early view" version of the journal Movement Disorders.

Parkinson's affects more than 1 million people in North America, most typically after age 60, according to the National Institutes of Health. It is a progressive disorder of the nervous system that primarily impacts balance and movement. At five years following diagnosis, approximately 50 percent of patients also experience cognitive decline.

Deficiencies of B12, which are more common in people with Parkinson's than the age-matched general population, are associated with weakness, tiredness, numbness, tingling and walking difficulties – symptoms that are found in Parkinson's disease.

Higher B12 Translates to Less Disability

Using patient data and archived blood samples from a prior study, known as DATATOP, the researchers divided three groups of 200-plus patients according to their levels of vitamin B12 at the beginning of the study. They found that over time, symptoms in those from the lower-level group developed more rapidly than in those in the higher bracket. Average annualized changes from preliminary testing for walking capacity were ranked at 1.53 for the group with lowest B12 levels, 0.83 for the middle group and 0.77 for the higher cohort, demonstrating twice the rate of progression between the groups with the lowest and highest B12 levels.

Additionally, researchers tested patients' blood levels of homocysteine, an amino acid that may be elevated in people with lower B12, and compared the levels to patients' results from the Mini Mental State Examination, a test that measures cognitive skills. The group with higher homocysteine levels, and thus lower B12, was found to decline by an annualized average of 1.96 points, versus a modest improvement (0.06 points) in those with lower homocysteine.

Supplement Intake, Parkinson's Meds Ruled Out Eligibility

Patients were eligible for the study if they had not started treatment for Parkinson's and if they had not been taking a vitamin supplement of greater strength than a standard daily multivitamin (containing up to 6 mcg of B12), in the month before the start of the study. The study endpoint was disease progression to a degree indicating readiness for levodopa, standard Parkinson's therapy that over time becomes less effective.

After preliminary testing, patients were offered the option of taking a daily multivitamin. Close to 50 percent of participants were found to have higher B12 on subsequent testing, suggesting that many took the supplement or improved their diets. For those patients who remained in a lower B12 level – suggesting they may not have started supplements – their annualized average increase of disability was 14.4 on the Unified Parkinson's Disease Rating Scale (UPDRS), a test that assesses activities of daily life, motor skills, behavior and mood. In contrast, for the group whose B12 levels began low but improved during the study, their average increase in the UPDRS score was 10, showing less disability.

"Our results suggest that the measurement of B12 levels early in Parkinson's may be beneficial," said Christine. "If levels are at the low end of normal, supplementation to get the level into the middle or upper end of the normal range may slow development of symptoms. But because we don't know the impact of B12 on Parkinson's disease, future studies are needed to determine if supplementing will change the trajectory."

Explore further: Caffeine as a biomarker for Parkinson's disease

More information: Chadwick W. Christine et al. Vitamin B12 and homocysteine levels predict different outcomes in early Parkinson's disease, Movement Disorders (2018). DOI: 10.1002/mds.27301

Related Stories

Caffeine as a biomarker for Parkinson's disease

February 15, 2018
Researchers at Juntendo University report in Neurology the potential use of blood levels of caffeine and its byproducts as biomarkers for Parkinson's disease. The finding is promising for the development of a method enabling ...

Caffeine level in blood may help diagnose people with Parkinson's disease

January 3, 2018
Testing the level of caffeine in the blood may provide a simple way to aid the diagnosis of Parkinson's disease, according to a study published in the January 3, 2018, online issue of Neurology, the medical journal of the ...

Protein levels in spinal fluid correlate to posture and gait difficulty in Parkinson's

February 21, 2018
Levels of a protein found in the brain called alpha-synuclein (α-syn) are significantly lower than normal in cerebrospinal fluid collected in Parkinson's disease patients suffering from postural instability and gait difficulty, ...

Blood biomarker could mark severe cognitive decline, quicker progression among Parkinson's patients

September 18, 2013
A genetic mutation, known as GBA, that leads to early onset of Parkinson's disease and severe cognitive impairment (in about 4 to 7 percent of all patients with the disease) also alters how specific lipids, ceramides and ...

High levels of urate in blood associated with lower risk of Parkinson's disease

January 13, 2016
Men who have high levels of urate, also known as uric acid, in their blood may be less likely to develop Parkinson's disease, according to a study published in the Jan. 13, 2016, online issue of Neurology, the medical journal ...

Statins may not be used for protection against Parkinson's disease

June 14, 2017
Use of statins may speed up the onset of Parkinson's disease symptoms in people who are susceptible to the disease, according to Penn State College of Medicine researchers.

Recommended for you

Early synaptic dysfunction found in Parkinson's Disease

May 24, 2018
Northwestern Medicine scientists identified a cellular mechanism that leads to neurodegeneration in patients with Parkinson's disease, according to a study published in Proceedings of the National Academy of Sciences.

Study uncovers cause of pesticide exposure, Parkinson's link

May 23, 2018
A new University of Guelph study has discovered why exposure to pesticides increases some people's risk of developing Parkinson's disease.

Link between tuberculosis and Parkinson's disease discovered

May 22, 2018
The mechanism our immune cells use to clear bacterial infections like tuberculosis (TB) might also be implicated in Parkinson's disease, according to a new collaborative study led by scientists from the Francis Crick Institute ...

Link between IBD and Parkinson's might allow doctors to slow down condition

May 21, 2018
Doctors may be able to modify or slow down the progress of the neurological condition Parkinson's disease in the future by spotting signs of it in patients with inflammatory bowel disease (IBD), suggest a study published ...

Untangling brain neuron dysfunction in Parkinson's disease and dementia with Lewy bodies

May 10, 2018
A decay of brain function is a hallmark of Parkinson's disease and dementia with Lewy bodies, or DLB. Specifically, cognitive dysfunction defines DLB, and nearly eight of every 10 Parkinson's patients develop dementia.

Diverse Parkinson's-related disorders may stem from different strains of same protein

May 9, 2018
Different Parkinson's-related brain disorders, called synucleionpathies, are characterized by misfolded proteins embedded in cells. Researchers in the Perelman School of Medicine at the University of Pennsylvania found that ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.